Abstract

In the view of progressively aging human population and increased occurrence of dysmetabolic disorders, such as diabetes mellitus, cognitive impairment becomes a major threat to the national health. To date, the molecular mechanisms of cognitive dysfunction are partially described for diabetes and diseases of different nature, such as Alzheimer disease or Parkinson disease. The emergence of data pointing towards pleotropic effects of hypoglycaemic medicines indicates involvement of their targets in pathogenesis of cognitive impairment. We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship of its targets to the pathogenesis of cognitive impairment.

摘要

鉴于人口逐渐老龄化和代谢异常疾病（例如糖尿病）的增加，认知障碍已成为对国民健康的主要威胁。迄今为止，认知功能障碍的分子机制部分描述了糖尿病和不同性质的疾病，如阿尔茨海默病或帕金森病。指向降血糖药物多效性的数据的出现表明它们的靶标参与了认知障碍的发病机制。我们的目标是回顾最广泛使用的降血糖药物格列本脲的可用数据，并找出其靶点与认知障碍发病机制的可能关系。